Two more cancer drugs have been provisionally banned for NHS after it was decided they were too expensive for the potential results.
Britain will be facing a bill of more than £15bn a year to diagnose and treat cancer in ten years time, new research has suggested.
The National Institute for Health and Clinical Excellence (NICE) has finalised new quality standards for end of life care for patients and their families and carers.
The National Institute for Health and Clinical Excellence (Nice) has banned another breast cancer drug from routine NHS use.
Axa PPP's Fergus Craig has a keen eye on PMI. Paul Robertson asks him how the market is improving.